Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Brief Summary: The primary objective of phase 1 is to evaluate the safety of KTE-C19 and atezolizumab combination regimens.

The primary objective of phase 2 is to evaluate the efficacy of KTE-C19 and atezolizumab, as measured by complete response rate in participants with refractory diffuse large B-cell lymphoma (DLBCL).

Participants who received an infusion of KTE-C19 will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968 (NCT05041309).


Options:
A: Arm Label: Phase 1 Cohort 1: KTE-C19 + ATZ (After 21 Days of KTE-C19); Type: EXPERIMENTAL; Interventions: Biological: KTE-C19, Biological: Atezolizumab, Drug: Cyclophosphamide, Drug: Fludarabine | Arm Label: Phase 1 Cohort 2: KTE-C19 + ATZ (After 14 Days of KTE-C19); Type: EXPERIMENTAL; Interventions: Biological: KTE-C19, Biological: Atezolizumab, Drug: Cyclophosphamide, Drug: Fludarabine | Arm Label: Phase 1 Cohort 3: KTE-C19 + ATZ (After 1 Day of KTE-C19); Type: EXPERIMENTAL; Interventions: Biological: KTE-C19, Biological: Atezolizumab, Drug: Cyclophosphamide, Drug: Fludarabine | Arm Label: Phase 2: KTE-C19 + ATZ (After 1 Day of KTE-C19); Type: EXPERIMENTAL; Interventions: Biological: KTE-C19, Biological: Atezolizumab, Drug: Cyclophosphamide, Drug: Fludarabine | Intervention Type: BIOLOGICAL; Name: KTE-C19; Assigned to Arm(s): Phase 1 Cohort 1: KTE-C19 + ATZ (After 21 Days of KTE-C19), Phase 1 Cohort 2: KTE-C19 + ATZ (After 14 Days of KTE-C19), Phase 1 Cohort 3: KTE-C19 + ATZ (After 1 Day of KTE-C19), Phase 2: KTE-C19 + ATZ (After 1 Day of KTE-C19) | Intervention Type: BIOLOGICAL; Name: Atezolizumab; Assigned to Arm(s): Phase 1 Cohort 1: KTE-C19 + ATZ (After 21 Days of KTE-C19), Phase 1 Cohort 2: KTE-C19 + ATZ (After 14 Days of KTE-C19), Phase 1 Cohort 3: KTE-C19 + ATZ (After 1 Day of KTE-C19), Phase 2: KTE-C19 + ATZ (After 1 Day of KTE-C19) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Phase 1 Cohort 1: KTE-C19 + ATZ (After 21 Days of KTE-C19), Phase 1 Cohort 2: KTE-C19 + ATZ (After 14 Days of KTE-C19), Phase 1 Cohort 3: KTE-C19 + ATZ (After 1 Day of KTE-C19), Phase 2: KTE-C19 + ATZ (After 1 Day of KTE-C19) | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Phase 1 Cohort 1: KTE-C19 + ATZ (After 21 Days of KTE-C19), Phase 1 Cohort 2: KTE-C19 + ATZ (After 14 Days of KTE-C19), Phase 1 Cohort 3: KTE-C19 + ATZ (After 1 Day of KTE-C19), Phase 2: KTE-C19 + ATZ (After 1 Day of KTE-C19)
B: Arm Label: Phase 1 Study: Axicabtagene Ciloleucel and Conditioning Chemotherapy; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: Phase 2 (Pivotal Study): Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: Phase 2 (Pivotal Study): Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: Phase 2 (Safety Management Study): Cohort 3; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide, Drug: Levetiracetam, Drug: Tocilizumab | Arm Label: Phase 2 (Safety Management Study): Cohort 4; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide, Drug: Levetiracetam, Drug: Tocilizumab, Drug: Dexamethasone, Drug: High-dose methylprednisolone, Drug: Bendamustine, Drug: Rituximab | Arm Label: Phase 2 (Safety Management Study): Cohort 5; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide, Drug: Levetiracetam, Drug: Rituximab, Drug: Doxorubicin, Drug: Prednisone, Drug: Vincristine, Drug: Ifosfamide, Drug: Carboplatin, Drug: Etoposide, Drug: Gemcitabine, Drug: Oxaliplatin, Drug: Cisplatin | Arm Label: Phase 2 (Safety Management Study): Cohort 6; Type: EXPERIMENTAL; Interventions: Biological: Axicabtagene Ciloleucel, Drug: Fludarabine, Drug: Cyclophosphamide, Drug: Levetiracetam, Drug: Tocilizumab, Drug: Dexamethasone, Drug: High-dose methylprednisolone, Drug: Bendamustine, Drug: Rituximab, Drug: Methylprednisolone | Intervention Type: BIOLOGICAL; Name: Axicabtagene Ciloleucel; Assigned to Arm(s): Phase 1 Study: Axicabtagene Ciloleucel and Conditioning Chemotherapy, Phase 2 (Pivotal Study): Cohort 1, Phase 2 (Pivotal Study): Cohort 2, Phase 2 (Safety Management Study): Cohort 3, Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 5, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): Phase 1 Study: Axicabtagene Ciloleucel and Conditioning Chemotherapy, Phase 2 (Pivotal Study): Cohort 1, Phase 2 (Pivotal Study): Cohort 2, Phase 2 (Safety Management Study): Cohort 3, Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 5, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Phase 1 Study: Axicabtagene Ciloleucel and Conditioning Chemotherapy, Phase 2 (Pivotal Study): Cohort 1, Phase 2 (Pivotal Study): Cohort 2, Phase 2 (Safety Management Study): Cohort 3, Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 5, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 3, Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 5, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Tocilizumab; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 3, Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: High-dose methylprednisolone; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 4, Phase 2 (Safety Management Study): Cohort 5, Phase 2 (Safety Management Study): Cohort 6 | Intervention Type: DRUG; Name: Doxorubicin; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Vincristine; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Ifosfamide; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 5 | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Phase 2 (Safety Management Study): Cohort 6
C: Arm Label: Cohort A; Type: EXPERIMENTAL; Interventions: Biological: CART-19 | Arm Label: Cohort B; Type: EXPERIMENTAL; Interventions: Biological: CART-19 | Arm Label: Cohort C; Type: EXPERIMENTAL; Interventions: Biological: CART-19 | Intervention Type: BIOLOGICAL; Name: CART-19; Assigned to Arm(s): Cohort A, Cohort B, Cohort C
D: Arm Label: CD19-7×19 CAR-T plus PD1 monoclonal antibody; Type: EXPERIMENTAL; Interventions: Biological: CD19-7×19 CAR-T plus PD1 monoclonal antibody | Intervention Type: BIOLOGICAL; Name: CD19-7×19 CAR-T plus PD1 monoclonal antibody; Assigned to Arm(s): CD19-7×19 CAR-T plus PD1 monoclonal antibody

Answer: A